Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Ocugen Inc (OCGN)

Ocugen Inc (OCGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration GlobeNewswire - Tue Mar 24, 6:45AM CDT

Optimal dose intended for Phase 3 demonstrates statistically significant reduction in lesion growth (31%) versus control at 12 months (p< 0.05) Potential 2X treatment benefit compared to 15% and 22%...

OCGN : 1.8100 (+3.43%)
Ocugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT to Discuss Phase 2 Clinical Trial Data for OCU410—Modifier Gene Therapy for Geographic Atrophy GlobeNewswire - Mon Mar 23, 6:02AM CDT

MALVERN, Pa., March 23, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced...

OCGN : 1.8100 (+3.43%)
Ocugen: Q4 Earnings Snapshot AP - Wed Mar 4, 7:32AM CST

Ocugen: Q4 Earnings Snapshot

OCGN : 1.8100 (+3.43%)
Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results GlobeNewswire - Wed Mar 4, 7:15AM CST

Enrollment for the OCU400 Phase 3 liMeliGhT clinical trial—the first and largest gene therapy registrational trial for broad retinitis pigmentosa patients—was completed. Topline Phase 3 data expected...

OCGN : 1.8100 (+3.43%)
Investors Eye Explosive Growth in Anti-Aging Therapies as Market Targets $420B Milestone FinancialNewsMedia - Tue Mar 3, 8:00AM CST

EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:GERN),(NASDAQ:NTLA),(NASDAQ:NAGE),(NASDAQ:OCGN) EQNX::TICKER_END

AVAI : 0.3200 (+10.34%)
NAGE : 4.41 (+3.04%)
GERN : 1.4900 (+5.67%)
NTLA : 12.82 (+10.04%)
OCGN : 1.8100 (+3.43%)
Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa GlobeNewswire - Mon Mar 2, 6:02AM CST

Enrollment for liMeliGhT, the first and largest gene therapy registrational trial for broad retinitis pigmentosa (RP) patients, was completed, reflecting strong interest from investigators and patients...

OCGN : 1.8100 (+3.43%)
Ocugen to Host Conference Call on Wednesday, March 4, 2026 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2025 Financial Results GlobeNewswire - Wed Feb 18, 6:02AM CST

MALVERN, Pa., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it...

OCGN : 1.8100 (+3.43%)
Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer GlobeNewswire - Mon Feb 9, 6:02AM CST

MALVERN, Pa., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the appointment...

OCGN : 1.8100 (+3.43%)
Ocugen, Inc. Announces Closing of $22.5 Million Underwritten Registered Direct Offering of Common Stock GlobeNewswire - Fri Jan 23, 7:00AM CST

MALVERN, Pa., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the closing of its previously...

OCGN : 1.8100 (+3.43%)
Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock GlobeNewswire - Wed Jan 21, 7:32AM CST

MALVERN, Pa., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the pricing of its underwritten...

OCGN : 1.8100 (+3.43%)

Barchart Exclusives

This Dividend King Is Down 26%. When Will It Bounce Back? Barchart - Tue Mar 31, 6:30PM CDT
Abbott Laboratories is down 26% from its 52-week high due to a soft quarter. With 54 consecutive years of dividend hikes and guidance calling for mid-single-digit organic sales growth plus 10% EPS expansion, the Dividend King seems discounted, but the question is, can it rebound? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.